Scholarlink

<p>Magnetic resonance imaging (MRI) and nuclear medicine imaging are widely used for cancer detection due to their high soft tissue resolution and sensitivity. Each modality has inherent limitations; therefore, integrated techniques such as positron emission tomography/magnetic resonance (PET/MR) have been developed. However, achieving simultaneous signal enhancement for both PET and MRI in clinical settings remains challenging. In this study, we employed gallium-68 (<sup>68</sup>Ga)-labelled NaGdF<sub>4</sub>@RGD nanoprobes as a model system to establish a synchronous PET/MR imaging strategy for tumor diagnosis. These nanoprobes exhibited suitable radiochemical half-life, and effective tumor-associated targeting, enabling successful PET/MR imaging across multiple tumor models, including hepatoma, renal cancer, and breast cancer <i>in vivo</i>. Notably, this imaging strategy allowed time-resolved visualization of nanoprobe distribution and prolonged retention behavior in orthotopic liver tumors during delayed imaging periods, providing imaging-based insights into nanomedicine pharmacodynamics.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synchronous PET/MR imaging and visualizing penetration of nanomedicine within tumor based on 68Ga-NaGdF4 probes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • Sitong Wu,
  • Wenyue Li,
  • Qi Yang,
  • Lele Song,
  • Wenpeng Huang,
  • Zhao Chen,
  • Bixiao Cui,
  • Jie Lu,
  • Yinghua Zou,
  • Yi Hou,
  • Lei Kang

摘要

Magnetic resonance imaging (MRI) and nuclear medicine imaging are widely used for cancer detection due to their high soft tissue resolution and sensitivity. Each modality has inherent limitations; therefore, integrated techniques such as positron emission tomography/magnetic resonance (PET/MR) have been developed. However, achieving simultaneous signal enhancement for both PET and MRI in clinical settings remains challenging. In this study, we employed gallium-68 (68Ga)-labelled NaGdF4@RGD nanoprobes as a model system to establish a synchronous PET/MR imaging strategy for tumor diagnosis. These nanoprobes exhibited suitable radiochemical half-life, and effective tumor-associated targeting, enabling successful PET/MR imaging across multiple tumor models, including hepatoma, renal cancer, and breast cancer in vivo. Notably, this imaging strategy allowed time-resolved visualization of nanoprobe distribution and prolonged retention behavior in orthotopic liver tumors during delayed imaging periods, providing imaging-based insights into nanomedicine pharmacodynamics.

Graphical abstract